Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to upend the pharma industry in the next few decades. Most promising is immunotheraphy, an approach being researched and advanced by Bristol-Myers (NYSE:BMY), Merck (NYSE:MRK), and Roche (Nasdaq:RHHBY), among others. While these drugs aren't cancer cures, they appear to be on pace to deliver significant improvements in the length of time cancer patients can expect to live, with a relatively tolerable side-effects.
Read the full article here:
http://www.investopedia.com/articles/investing/082013/will-immunotherapy-disrupt-oncology-market.asp
Investopedia: Will Immunotherapy Disrupt The Oncology Market?
0 comments:
Post a Comment